Clinical Review: Familial Mediterranean Fever—An Overview of Pathogenesis, Symptoms, Ocular Manifestations, and Treatment

References

• Heller H, Sohar E, Pras M. Ethnic distribution and amyloidosis in familial Mediterranean fever (FMF). Pathol Microbiol. 1961;24:718–723
   PubMedGoogle Scholar
• Pras M, Pras E, Kastner D. The origin of the FMF gene. Isr J Med Sci. 1995;31:503–504
   PubMedGoogle Scholar
• Samuels J, Aksentijevich I, Torosyan Y, et al. Familial Mediterranean fever at the millennium: clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore). 1998;77:268–297
   PubMed Web of Science ®Google Scholar
• Stoffman N, Magal N, Shohat T, et al. Higher than expected carrier rates for familial Mediterranean fever in various Jewish ethnic groups. Eur J Hum Genet. 2000;8:307–310
   PubMed Web of Science ®Google Scholar
• Jesus AA, Fujihira E, Watase M, et al. Hereditary autoinflammatory syndromes: a Brazilian multicenter study. J Clin Immunol. 2012;32:922–932
   PubMed Web of Science ®Google Scholar
• Migita K, Uehara R, Nakamura Y, et al. Familial Mediterranean fever in Japan. Medicine (Baltimore). 2012;91:337–343
   PubMed Web of Science ®Google Scholar
• Robinson BW, Joske RA. Familial Mediterranean fever in Australia. Med J Aust. 1980;1:77--78
   PubMed Web of Science ®Google Scholar
• Ben-Chetrit E, Touitou I. Familial mediterranean fever in the world. Arthritis Rheum. 2009;61:1447–1453
   PubMed Web of Science ®Google Scholar
• Aksentijevich I, Pras E, Gruberg L, et al. Refined mapping of the gene causing familial Mediterranean fever, by linkage and homozygosity studies. Am J Hum Genet. 1993;53:451–461
   PubMed Web of Science ®Google Scholar
• French FMFC. A candidate gene for familial Mediterranean fever. Nature Genet. 1997;17:25–31
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Quartier P, So A, Hawkins PN. The emerging role of interleukin-1beta in autoinflammatory diseases. Arthritis Rheum. 2011;63:314–324
   PubMed Web of Science ®Google Scholar
• Milhavet F, Cuisset L, Hoffman HM, et al. The infevers autoinflammatory mutation online registry: update with new genes and functions. Hum Mutat. 2008;29:803–808
   PubMed Web of Science ®Google Scholar
• Sarrauste de Menthiere C, Terriere S, et al. INFEVERS: the Registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res. 2003;31:282–285
   PubMed Web of Science ®Google Scholar
• Touitou I, Lesage S, McDermott M, et al. Infevers: an evolving mutation database for auto-inflammatory syndromes. Hum Mutat. 2004;24:194–198
   PubMed Web of Science ®Google Scholar
• Consortium TIF. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell. 1997;90:797–807
   PubMed Web of Science ®Google Scholar
• Bernot A, da Silva C, Petit JL, et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). Hum Mol Genet. 1998;7:1317–1325
   PubMed Web of Science ®Google Scholar
• Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet. 1998;351:659–664
   PubMed Web of Science ®Google Scholar
• Mankan AK, Kubarenko A, Hornung V. Immunology in clinic review series; focus on autoinflammatory diseases: inflammasomes: mechanisms of activation. Clin Exp Immunol. 2012;167:369–381
   PubMed Web of Science ®Google Scholar
• Seshadri S, Duncan MD, Hart JM, et al. Pyrin levels in human monocytes and monocyte-derived macrophages regulate IL-1beta processing and release. J Immunol. 2007;179:1274–1281
   PubMed Web of Science ®Google Scholar
• Papin S, Cuenin S, Agostini L, et al. The SPRY domain of pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ. 2007;14:1457–1466
   PubMed Web of Science ®Google Scholar
• Legrand-Poels S, Esser N, L'Homme L, et al. Free fatty acids as modulators of the NLRP3 inflammasome in obesity/type 2 diabetes. Biochem Pharmacol. 2014;92:131--141
   PubMed Web of Science ®Google Scholar
• Tan MS, Yu JT, Jiang T, et al. The NLRP3 inflammasome in Alzheimer's disease. Mol Neurobiol. 2013;48:875–882
   PubMed Web of Science ®Google Scholar
• Taskiran EZ, Cetinkaya A, Balci-Peynircioglu B, et al. The effect of colchicine on pyrin and pyrin interacting proteins. J Cell Biochem. 2012;113:3536–3546
   PubMed Web of Science ®Google Scholar
• Mansfield E, Chae JJ, Komarow HD, et al. The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments. Blood. 2001;98:851–859
   PubMed Web of Science ®Google Scholar
• Chae JJ, Wood G, Masters SL, et al. The B30. 2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1β production. Proc Natl Acad Sci U S A. 2006;103:9982–9987
   PubMed Web of Science ®Google Scholar
• Chae JJ, Wood G, Richard K, et al. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. Blood. 2008;112:1794–1803
   PubMed Web of Science ®Google Scholar
• Direskeneli H, Ozdogan H, Korkmaz C, et al. Serum soluble intercellular adhesion molecule 1 and interleukin 8 levels in familial Mediterranean fever. J Rhemuatol. 1999;26:1983–1986
   PubMed Web of Science ®Google Scholar
• Berkun Y, Padeh S, Reichman B, et al. A single testing of serum amyloid a levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever. Semin Arthritis Rheum. 2007;37:182–188
   PubMed Web of Science ®Google Scholar
• Aypar E, Ozen S, Okur H, et al. Th1 polarization in familial Mediterranean fever. J Rheumatol. 2003;30:2011–2013
   PubMed Web of Science ®Google Scholar
• Kone-Paut I, Hentgen V, Touitou I. Current data on familial Mediterranean fever. Joint Bone Spine. 2011;78:111–114
   PubMed Web of Science ®Google Scholar
• Proceedings of the First International Conference on FMF [press release]. London and Tel Aviv: Freund Publishing House, 1997:157--161
   Google Scholar
• Yalcinkaya F, Ozen S, Ozcakar ZB, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford). 2009;48:395–398
   PubMed Web of Science ®Google Scholar
• Lidar M, Yaqubov M, Zaks N, et al. The prodrome: a prominent yet overlooked pre-attack manifestation of familial Mediterranean fever. J Rheumatol. 2006;33:1089–1092
   PubMed Web of Science ®Google Scholar
• Jarjour R, Al-Berrawi S. Familial Mediterranean fever in Syrian children: phenotype–genotype correlation. Rheumatol Int. 2014 August 24; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Berkun Y, Ben-Chetrit E, Klar A, Ben-Chetrit E. Peritoneal adhesions and intestinal obstructions in patients with familial Mediterranean fever—are they more frequent? Semin Arthritis Rheum. 2007;36:316–321
   PubMed Web of Science ®Google Scholar
• Brik R, Shinawi M, Kasinetz L, Gershoni-Baruch R. The musculoskeletal manifestations of familial Mediterranean fever in children genetically diagnosed with the disease. Arthritis Rheum. 2001;44:1416–1419
   PubMed Web of Science ®Google Scholar
• Majeed HA, rawashdeh M. The clinical patterns of arthritis in children with familial Mediterranean fever. QJM. 1997;90:37–43
   PubMed Web of Science ®Google Scholar
• Tunca M, Akar S, Onen F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 2005;84:1–11
   PubMed Web of Science ®Google Scholar
• Kees S, Langevitz P, Zemer D, et al. Attacks of pericarditis as a manifestation of familial Mediterranean fever (FMF). QJM. 1997;90:643–647
   PubMed Web of Science ®Google Scholar
• Kavukcu S, Turkmen M, Soylu A, et al. Skin and muscle involvement as presenting symptoms in four children with familial Mediterranean fever. Clin Rheumatol. 2009;28:857–860
   PubMed Web of Science ®Google Scholar
• Lidar M, Doron A, Barzilai A, et al. Erysipelas-like erythema as the presenting feature of familial Mediterranean fever. J Eur Acad Dermatol Venereol. 2013;27:912–915
   PubMed Web of Science ®Google Scholar
• Herlin T, Storm K, Hamborg-Petersen B. Remission of progressive renal failure in familial Mediterranean fever during colchicine treatment. Arch Dis Child. 1985;60:477–479
   PubMed Web of Science ®Google Scholar
• Peleg H, Ben-Chetrit E. The kidney in familial Mediterranean fever. J Rheumatol. 2013;40:1948–1950
   PubMed Web of Science ®Google Scholar
• Medlej-Hashim M, Delague V, Chouery E, et al. Amyloidosis in familial Mediterranean fever patients: correlation with MEFV genotype and SAA1 and MICA polymorphisms effects. BMC Med Genet. 2004;5:4
   PubMedGoogle Scholar
• Ben-Chetrit E. Familial Mediterranean fever (FMF) and renal AA amyloidosis—phenotype–genotype correlation, treatment and prognosis. J Nephrol. 2003;16:431–434
   PubMed Web of Science ®Google Scholar
• Tekin M, Yalcinkaya F, Cakar N, et al. MEFV mutations in multiplex families with familial Mediterranean fever: is a particular genotype necessary for amyloidosis? Clin Genet. 2000;57:430–434
   PubMed Web of Science ®Google Scholar
• Mimouni A, Magal N, Stoffman N, et al. Familial Mediterranean fever: effects of genotype and ethnicity on inflammatory attacks and amyloidosis. Pediatrics. 2000;105:E70
   PubMed Web of Science ®Google Scholar
• Michaelson I, Eliakim M, Ehrenfeld EN, Rachmilewitz M. Fundal changes resembling colloid bodies in recurrent polyserositis (periodic disease). AMA Arch Ophthalmol. 1959;62:1–4
   PubMed Web of Science ®Google Scholar
• Shapiro TR, Ehrenfeld EN. Recurrent polyserositis (“periodic disease,” “familial Mediterranean fever”) in children. Pediatrics. 1962;30:443–449
   PubMed Web of Science ®Google Scholar
• Baghdassarian SA, Armenian HK, Khachadurian AK. Absence of ophthalmoscopic changes in familial paroxysmal polyserositis. Arch Ophthalmol. 1972;88:607–608
   PubMed Web of Science ®Google Scholar
• Yazici H, Pazarli H. Eye involvement in a patient with familial Mediterranean fever. J Rheumatol. 1982;9:644
   PubMed Web of Science ®Google Scholar
• Scharf J, Meyer E, Zonis S. Episcleritis associated with familial Mediterranean fever. Am J Ophthalmol. 1985;100:337–339
   PubMed Web of Science ®Google Scholar
• Akman A, Varan B, Akova YA, Aydin P. Ocular involvement in siblings with familial mediterranean fever. J Pediatr Ophthalmol Strabismus. 2001;38:114–116
   PubMed Web of Science ®Google Scholar
• Berestizschevsky S, Weinberger D, Avisar I, Avisar R. Episcleritis associated with familial Mediterranean fever. Isr Med Assoc J. 2008;10:318–319
   PubMed Web of Science ®Google Scholar
• Yazici A, Ozdal P, Yuksekkaya P, et al. Ophthalmic manifestations in familial Mediterranean fever: a case series of 6 patients. Eur J Ophthalmol. 2014;24:593–598
   PubMed Web of Science ®Google Scholar
• Ozaltin F, Bakkaloglu A, Orhon M, et al. Bilateral uveitis in a 7-year-old patient with familial Mediterranean fever: an extremely rare complication. Clin Exp Rheumatol. 2001;19:S80–S81
   PubMed Web of Science ®Google Scholar
• BenEzra D. Clinical aspects and diagnostic guidelines of ocular Behcet's disease. Dev Ophthamol. 1999;31:109–117
   PubMedGoogle Scholar
• González-Gay MA, García-Porrúa C, Brañas F, et al. Epidemiologic and clinical aspects of Behcet's disease in a defined area of Northwestern Spain, 1988–1997. J Rheumatol. 2000;27:703–707
   PubMed Web of Science ®Google Scholar
• Bang D, Lee JH, Lee ES, et al. Epidemiologic and clinical survey of Behcet's disease in Korea: the first multicenter study. J Korean Med Sci. 2001;16:615–618
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Kotter I, Djawari D, et al. Epidemiological features of Adamantiades-Behcet's disease in Germany and in Europe. Yonsei Med J. 1997;38:411–422
   PubMedGoogle Scholar
• BenEzra D, Nussenblatt R. Ocular manifestations of Behcet's disease. J Oral Pathol. 1978;7:431–435
   PubMedGoogle Scholar
• Altiparmak UE, Koklu B, Unlu N, et al. Macular involvement in secondary systemic amyloidosis. Eur J Ophthalmol. 2008;18:459–461
   PubMed Web of Science ®Google Scholar
• Satoh S, Itoh C, Nakamura N. [A case of frosted branch angiitis associated with retinal vein occlusion as a complication of familial Mediterranean fever]. Nihon Ganka Gakkai Zasshi. 2010;114:621–628
   PubMedGoogle Scholar
• Leibovitch I, Alster Y, Scherrmann JM, et al. Colchicine in tear fluid of treated patients with familial Mediterranean fever. Cornea. 2003;22:191–193
   PubMed Web of Science ®Google Scholar
• Biedner BZ, Rothkoff L, Friedman L, Geltman C. Colchicine suppression of corneal healing after strabismus surgery. Br J Ophthalmol. 1977;61:496–497
   PubMed Web of Science ®Google Scholar
• Lazar M, Rothkoff L. Colchicine and ocular surface changes in familial Mediterranean fever. Acta Ophthalmol. 2010;88:e5; author reply e6
   PubMedGoogle Scholar
• Karalezli A, Borazan M, Yilmaz S, et al. Conjunctival impression cytology and tear-film changes in patients with familial Mediterranean fever. Acta Ophthalmol. 2009;87:39–43
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Wolff SM, Goldfinger SE, et al. Colchicine therapy for familial mediterranean fever: a double-blind trial. N Engl J Med. 1974;291:934–937
   PubMed Web of Science ®Google Scholar
• Goldstein RC, Schwabe AD. Prophylactic colchicine therapy in familial Mediterranean fever: a controlled, double-blind study. Ann Intern Med. 1974;81:792–794
   PubMed Web of Science ®Google Scholar
• Cheung MW, Pugliese AC. The use of colchicine for the treatment of familial Mediterranean fever. J Med Soc New Jersey. 1975;72:735–736
   PubMedGoogle Scholar
• Ozturk MA, Kanbay M, Kasapoglu B, et al. Therapeutic approach to familial Mediterranean fever: a review update. Clin Exp Rheumatol. 2011;29:S77–S86
   PubMed Web of Science ®Google Scholar
• Lidar M, Yonath H, Shechter N, et al. Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev. 2012;12:72–76
   PubMed Web of Science ®Google Scholar
• Lidar M, Scherrmann JM, Shinar Y, et al. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum. 2004;33:273–282
   PubMed Web of Science ®Google Scholar
• Uludag A, Silan C, Atik S, et al. Relationship between response to colchicine treatment and MDR1 polymorphism in familial Mediterranean fever patients. Genet Test Mol Biomarkers. 2014;18:73–76
   PubMed Web of Science ®Google Scholar
• Hashkes PJ, Spalding SJ, Giannini EH, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012;157:533–541
   PubMed Web of Science ®Google Scholar
• Mitroulis I, Skendros P, Oikonomou A, et al. The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis. Ann Rheum Dis. 2011;70:1347–1348
   PubMed Web of Science ®Google Scholar
• Hacihamdioglu DO, Ozen S. Canakinumab induces remission in a patient with resistant familial Mediterranean fever. Rheumatology (Oxford). 2012;51:1041
   PubMed Web of Science ®Google Scholar
• Brik R, Butbul-Aviel Y, Lubin S, et al. Canakinumab for children with colchicine-resistant familial Mediterranean fever: a 6-month, open-label, single-arm, pilot study. Arthritis Rheumatol. 2014;66:3241--3243
   PubMed Web of Science ®Google Scholar
• Bilgen SA, Kilic L, Akdogan A, et al. Effects of anti-tumor necrosis factor agents for familial Mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment. J Clin Rheumatol. 2011;17:358–362
   PubMed Web of Science ®Google Scholar
• Salehzadeh F, Jahangiri S, Mohammadi E. Dapsone as an alternative therapy in children with familial Mediterranean Fever. Iran J Pediatr. 2012;22:23–27
   PubMed Web of Science ®Google Scholar